Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Source: Benzinga
Lyft's Quarterly Performance: Lyft, Inc. shares surged 21.5% in pre-market trading after reporting quarterly losses of three cents per share and revenue of $1.52 billion, both exceeding analyst expectations.
Market Movements: Several stocks experienced significant pre-market trading fluctuations, with AtlasClear Holdings gaining 89.6% and Digital Turbine falling 41.1% following their respective earnings reports.
Analyst Views on TOI
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.360
Low
6.00
Averages
7.00
High
8.00
Current: 3.360
Low
6.00
Averages
7.00
High
8.00
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
